Search alternatives:
means decrease » mean decrease (Expand Search), deaths decreased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
data decrease » rate decreased (Expand Search), a decrease (Expand Search), deaths decreased (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
i means » _ means (Expand Search), k means (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
Showing 1 - 20 results of 5,734 for search '(((( cloud ((data decrease) OR (_ decrease)) ) OR ( i means decrease ))) OR ( i large decrease ))', query time: 0.94s Refine Results
  1. 1
    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth.

    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
    Save to List
    Saved in:
  5. 5
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection.

    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

    Published 2024
    Save to List
    Saved in:
  8. 8
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Point cloud fusion instance effect.

    Point cloud fusion instance effect. by Hongliang Zou (20707270)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Comparison of the studied complete blood count parameters between <i>Anaplasma</i> spp. and <i>A. ovis</i> positive and negative goats enrolled from Dera Ghazi Khan district in Punjab. Data is represented as mean ± standard error of mean. P-value indicates the result of two-sample t test calculated for each studied parameter.

    Comparison of the studied complete blood count parameters between <i>Anaplasma</i> spp. and <i>A. ovis</i> positive and negative goats enrolled from Dera Ghazi Khan district in Pun... by Sumaira Sumaira (21453523)

    Published 2025
    Save to List
    Saved in:
  14. 14
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation.

    Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

    Published 2024
    “…(D) Immunoblot showing p53 protein expression is decreased in colon tissue from 5-month old HA-MAD1 mice after 1 week of 6 mg/kg dox feed as compared to control. …”
    Save to List
    Saved in:
  17. 17
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: